Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282934 | 0.72 | TLR8 (0.36) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31277709 | 0.70 | NPC1 (0.50) | ALOX12SMN1; SMN2HTTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL31277933 | 0.70 | SMN1; SMN2 (0.52) | ALOX12SMN1; SMN2HTTKMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL31278009 | 0.70 | SMN1; SMN2 (0.52) | ALOX12SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL31277600 | 0.70 | ALDH1A1 (0.53) | ALOX12SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL22610225 | 0.68 | HDAC3 (0.73) | ALOX12SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL1023091 | 0.68 | MEN1 (0.58) | ALOX12SMN1; SMN2HTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31277731 | 0.67 | SMN1; SMN2 (0.51) | ALOX12SMN1; SMN2HTTKMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL31277594 | 0.67 | NPC1 (0.51) | ALOX12SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL23023795 | 0.67 | HDAC3 (0.76) | ALOX12SMN1; SMN2HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542678-B1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | SOLVAY PHARM BV (NL) | 2010-02-24 | — | — | EP | disclosed |
| US-7319110-B2 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-15 | — | — | US | disclosed |
| EP-1753413-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB SB 1/SB -ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039550-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | CNR1, CNR2, GPR3 | ALOX12 2811/4885SMN1; SMN2 2386/4885HTT 3320/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | ALOX12 679/4885SMN1; SMN2 1727/4885HTT 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.